Next Step in Treating Alzheimer’s
Jülich/Leipzig, 4 February 2021 – The Alzheimer’s drug candidate PRI-002, which was developed at Forschungszentrum Jülich, can now enter the next phase of development. SPRIND, the German Federal Agency for Disruptive Innovation, is supporting the development of the new therapeutic approach for treating Alzheimer’s disease. The therapeutic agent can now be tested on Alzheimer’s patients in a phase II clinical study. PRI-002 was proven safe and tolerable for daily use in humans in a phase I clinical study over four weeks in spring 2019.